Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-25T00:29:24.811Z Has data issue: false hasContentIssue false
  • English
  • Français

Metoclopramide and Haloperidol in Tardive Dyskinesia

Published online by Cambridge University Press:  29 January 2018

D. N. Bateman ,
D. K. Dutta ,
H. A. McClelland  and
M. D. Rawlins
D. N. Bateman
Affiliation:
Department of Pharmacological Sciences, (Wolfson Unit of Clinical Pharmacology), The University, Newcastle upon Tyne, NE1 7RU
D. K. Dutta
Affiliation:
Department of Pharmacological Sciences, (Wolfson Unit of Clinical Pharmacology), The University, Newcastle upon Tyne, NE1 7RU
H. A. McClelland
Affiliation:
St Nicholas Hospital, Gosforth, Newcastle upon Tyne, NE3 3XT
M. D. Rawlins
Affiliation:
St Nicholas Hospital, Gosforth, Newcastle upon Tyne, NE3 3XT
Get access Rights & Permissions [Opens in a new window]

Summary

The effect of single intravenous doses of metoclopramide (10 mg, 20 mg and 40 mg) and haloperidol (5 mg and 10 mg) have been compared to placebo (saline) in a double blind randomised study in 8 patients with tardive dyskinesia secondary to neuroleptic therapy. Tardive dyskinesia rating scores were improved significantly (P <0.01) 6 hours after dosing by metoclopramide 40 mg, and haloperidol 5 mg and 10 mg, when compared to placebo. Single doses of dopamine receptor blocking agents improve tardive dyskinesia. The dose of metoclopramide required to show a beneficial effect was high, and this therefore suggests that it is unlikely to be of therapeutic value as the incidence of adverse reactions would be greatly increased. By monitoring the effects of single doses of dopamine receptor blocking drugs in patients with tardive dyskinesia it is possible to compare the relative potencies of these drugs on dopaminergic systems in vivo in man.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 135 , Issue 6 , December 1979 , pp. 505 - 508
Copyright
Copyright © Royal College of Psychiatrists, 1979 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bateman, D. N., Kahn, C. & Davies, D. S. (1979) Concentration effect studies with oral metoclopramide. British Journal of Clinical Pharmacology, 8, 179–82.CrossRefGoogle ScholarPubMed
Bateman, D. N., Kahn, C., Legg, N. J. & Reid, J. L. (1978a) Metoclopramide in Parkinson's disease. Clinical Pharmacology and Therapeutics, 24, 459–64.CrossRefGoogle ScholarPubMed
Bateman, D. N., Kahn, C., Mashiter, K. & Davies, D. S. (1978b) Pharmacokinetics and concentration-effect studies with intravenous metoclopramide. British Journal of Clinical Pharmacology, 6, 401–7.CrossRefGoogle ScholarPubMed
Borenstein, P. & Bles, G. (1965) Effects cliniques et electroencephalographiques du metoclopramide en psychiatric Therapie, 20, 75–95.Google Scholar
Calne, D. B., Reid, J. L., Vakil, S. D., Rao, S., Petrie, A., Pallis, C. A., Gawler, J., Thomas, P. K. & Millson, A. (1971) Idiopathic parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. British Medical Journal, iii, 729–32.Google Scholar
Casteels Van Daele, M., Jaeken, J., Van Der Schueren, P., Zimmerman, A. & Van Den Bon, P. (1970) Dystonic reactions in children caused by metoclopramide. Archives of Diseases of Childhood, 45, 130–3.CrossRefGoogle ScholarPubMed
Committee on Safety of Medicines (1975) Current Problems, 1.Google Scholar
Forsman, A. & Ohman, R. (1975) Some aspects of the distribution and metabolism of haloperidol in man. In: Antipsychotic drugs: Pharmacodynamics and Pharmacokinetics, (ed. Sevral, G.).Google Scholar
Goldberg, L. I., Volkman, P. H. & Kohli, J. D. (1978) A comparison of the vascular dopamine receptor with other dopamine receptors. Annual Review of Pharmacology and Toxicology, 18, 57–79.CrossRefGoogle ScholarPubMed
Inoue, F. (1979) Adverse reactions of antipsychotic drugs. Drug Intelligence and Clinical Pharmacy, 13, 198–208.CrossRefGoogle Scholar
Kataria, M., Traub, M. & Marsden, C. D. (1978) Extrapyramidal side effects of metoclopramide. Lancet, ii, 1254–5.Google Scholar
Kebebian, J. W. & Calne, D. B. (1979) Multiple receptors for dopamine. Nature, 277, 93–6.Google Scholar
Klawans, H. L. (1973) The pharmacology of tardive dyskinesias. American Journal of Psychiatry, 130, 82–6.CrossRefGoogle ScholarPubMed
Kobayashi, R. M. (1977) Drug therapy of tardive dyskinesias. New England Journal of Medicine, 296, 257–60.Google Scholar
Lavy, S., Melamed, E. & Penchas, S. (1978) Tardive dyskinesia associated with metoclopramide. British Medical Journal, i, 77–8.Google Scholar
Marcucci, F., Airoldi, L., Mussini, E. & Garattini, S. (1971/2) Distribution of haloperidol and trifluperidol in brain and blood of rats. Chemical-Biological Interactions, 4, 427–30.Google Scholar
N.I.M.H. Psychopharmacology Research Branch (1975) Development of a dyskinetic movement scale. Early Clinic Drug Evaluation Unit Intercom, 4, 3–6.Google Scholar
Siegel, S. (1956) Nonparametric Statistics for the Behavioural Sciences. New York: McGraw–Hill.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.